Association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma in the Phase III CELESTIAL trial

Basit Öğe Kaydı
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.contributor.authorStrasser, S.
dc.contributor.authorAbou-Alfa, G.
dc.contributor.authorMeyer, T.
dc.contributor.authorCheng, A.
dc.contributor.authorCicin, I.
dc.contributor.authorBolondi, L.
dc.contributor.authorKlumpen, H.
dc.date.accessioned2024-06-12T11:24:07Z
dc.date.available2024-06-12T11:24:07Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.endpage34en_US
dc.identifier.issn0815-9319
dc.identifier.issn1440-1746
dc.identifier.startpage33en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/26814
dc.identifier.volume34en_US
dc.identifier.wosWOS:000483843100049en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal Of Gastroenterology And Hepatologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titleAssociation of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma in the Phase III CELESTIAL trialen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu